Posts

The role of cannabinoids in neurodevelopmental disorders of children and adolescents

/by

Neurodevelopmental disorders have a multifactorial etiology that results from the interaction between biological and environmental factors. The biological basis of many of these disorders is only partially understood, which makes therapeutic interventions, especially pharmacological ones, particularly difficult. The impact of medical cannabis on neurological and psychiatric disorders has been studied for a long time. This study aimed to review the currently available clinical and pre-clinical studies regarding the use of cannabinoids in pediatric neurodevelopmental disorders and to draw attention to the potential therapeutic role of cannabidiol in this field.

Read more

Cannabidiol Cigarettes as Adjunctive Treatment for Psychotic Disorders – A Randomized, Open-Label Pilot-Study

/by

The main aim of the study was to clarify the antipsychotic potential of CBD used as adjunctive therapy simulating a naturalistic setting. Our trial is the first study evaluating the effects of smoked CBD-cigarettes as adjunctive therapy for psychotic symptoms.

Read more

Opposite Roles for Cannabidiol and δ-9-Tetrahydrocannabinol in Psychotomimetic Effects of Cannabis Extracts: A Naturalistic Controlled Study

/by

Although δ-9-tetrahydrocannabinol (THC), the main cannabinoid from the cannabis plant, is responsible for the psychotomimetic effects of cannabis, cannabidiol (CBD), the second most abundant cannabinoid in the cannabis plant, does not show any psychotomimetic effect. Cannabidiol has even been proposed to be antipsychotic and to counteract some of the psychotomimetic effects of THC. The aim of this study was to test the potential antipsychotomimetic effects of CBD.

Read more

Cannabidiol for psychosis: A review of 4 studies

/by

Authors: Sy Atezaz Saeed, MD, MS, and Kathryn E. Clary, BA Published in Current Psychiatry June 2020   Introduction There has been increasing interest in the medicinal use of cannabidiol…

Read more

Cannabis consumption and non-alcoholic fatty liver disease. A three years longitudinal study in first episode non-affective psychosis patients.

/by

Authors: Javier Vázquez-Bourgon, Víctor Ortiz-García de la Foz, Irene Suarez-Pereira, et al
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 20 December 2019
—
INTRODUCTION: Increased incidence of obesity and excess weight lead to an increased incidence of non-alcoholic fatty liver disease (NAFLD). Recent evidence indicates a protective effect of cannabis consumption on weight gain and related metabolic alterations in psychosis patie…

Read more

Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials.

/by

Authors: Serena Silvestro, Santa Mammana, Eugenio Cavalli, Placido Bramanti, Emanuela Mazzon
Molecules, April 2019
—
Cannabidiol (CBD) is one of the cannabinoids with non-psychotropic action, extracted from Cannabis sativa. CBD is a terpenophenol and it has received a great scientific interest thanks to its medical applications. This compound showed efficacy as anti-seizure, antipsychotic, n…

Read more

The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis.

/by

Authors: Britta Hahn
Schizophrenia Bulletin, 13 January 2018
—
A major factor associated with poor prognostic outcome after a first psychotic break is cannabis misuse, which is prevalent in schizophrenia and particularly common in individuals with recent-onset psychosis. Behavioral interventions aimed at reducing cannabis use have been un…

Read more

Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia.

/by

Authors: F. M. Leweke, D. Piomelli, F. Pahlisch, D. Muhl, C. W. Gerth, C. Hoyer, J. Klosterkötter, et al
Translational Psychiatry, 20 March 2012
—
Cannabidiol is a component of marijuana that does not activate cannabinoid receptors, but moderately inhibits the degradation of the endocannabinoid anandamide. We previously reported that an elevation of anandamide levels in cerebrospinal fluid inversely correlated to psychot…

Read more

Synthetic delta-9-tetrahydrocannabinol (dronabinol) can improve the symptoms of schizophrenia.

/by

Authors: Glenn Schwarcz, Basawaraj Karajgi, Richard McCarthy
Journal of Clinical Psychopharmacology, June 2009
—
We are reporting improvement of symptoms of schizophrenia in a small group of patients who received the cannabinoid agonist dronabinol (synthetic Delta-9-tetrahydrocannabinol). Before this report, cannabinoids had usually been associated with worsening of psychotic symptoms. I…

Read more

Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.

/by

Authors: A.W. Zuardi, J.A.S. Crippa, J.E.C. Hallak, F.A. Moreira, F.S. Guimarães
Brazilian journal of medical and biological research, April 2006
—
A high dose of delta9-tetrahydrocannabinol, the main Cannabis sativa (cannabis) component, induces anxiety and psychotic-like symptoms in healthy volunteers. These effects of delta9-tetrahydrocannabinol are significantly reduced by cannabidiol (CBD), a cannabis constituent whi…

Read more